BioLineRx (BLRX) EV to CFO (2015 - 2026)
Analysis
BioLineRx (BLRX) EV to CFO (2015 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.27 Bn | 131.42 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.55 Bn | 77.56 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.45 Bn | 58.27 Bn | 1.37 Bn |
| 4 | Moderna | 57.73 Bn | 52.59 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.08 Bn | 44.08 Bn | - |
| 6 | BeOne Medicines | 39.95 Bn | 34.85 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.14 Bn | 31.84 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - |
| 9 | Insmed | 27.32 Bn | 26.16 Bn | 358.27 Mn |
| 10 | BioLineRx | 6.68 Bn | 6.68 Bn | 235,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -2,528.91 |
| Mar 31, 2026 | -2,627.93 |
| Dec 31, 2025 | -2,255.07 |
| Sep 30, 2025 | -2,146.22 |
| Jun 30, 2025 | -30,775.11 |
| Mar 31, 2025 | -1,358.56 |
| Dec 31, 2024 | -1,166.61 |
| Sep 30, 2024 | -2,385.87 |
| Jun 30, 2024 | -2,183.26 |
| Mar 31, 2024 | -3,448.23 |
| Dec 31, 2023 | 13,663.56 |
| Sep 30, 2023 | -6,783.70 |
| Jun 30, 2023 | -6,097.56 |
| Mar 31, 2023 | -4,093.57 |
| Dec 31, 2022 | -3,823.82 |
| Sep 30, 2022 | -3,057.65 |
| Jun 30, 2022 | -5,815.37 |
| Mar 31, 2022 | -8,747.96 |
| Dec 31, 2021 | -10,594.15 |
| Sep 30, 2021 | -5,535.74 |